Posted May 24, 2021
Exclusive: NIH spinout raises millions to attack drug-resistant cancers with RNA. It has big plans.
The startup is developing therapeutics for drug-resistant cancers — and applying its technology to other arenas, including Covid-19.
Read the full story from the Washington Business Journal.